FDA guidance
Cilastatin Sodium; Imipenem; Relebactam (Powder - Intravenous)
FDA guidance · Draft · issued Jul 15, 2021
Key facts
| Title | Cilastatin Sodium; Imipenem; Relebactam (Powder - Intravenous) |
|---|---|
| Status | Draft |
| Issue date | Jul 15, 2021 |
| Center | Center for Drug Evaluation and Research |
| Regulated product | Drugs |
| Topics | Product-Specific Guidance |
| Document on fda.gov | accessdata.fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents